Moderna (MRNA) is not aware of any significant intellectual property impediments for any products it intends to commercialize, including mRNA-1273

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today released a statement on the July 23rd U.S. Patent Trial and Appeal Board (PTAB) ruling:

The recently issued Patent Trial and Appeal Board ruling on the 8,058,069 patent relates to Moderna’s challenge to certain legacy patents held by Arbutus, commenced well before the development of mRNA-1273. These actions were taken by Moderna in response to the longstanding aggressive posture taken by Arbutus and its predecessor company against many developers of nucleic acid-based therapeutics. Through its actions, Moderna successfully overturned one legacy patent held by Arbutus and invalidated the broadest claims of a second one. Moderna’s continued development of its proprietary LNP formulation technology and manufacturing processes have advanced well beyond the technology described in these legacy Arbutus patents. Our improved proprietary LNP formula, used to manufacture mRNA-1273, is not covered by the Arbutus patents. Moderna is not aware of any significant intellectual property impediments for any products we intend to commercialize, including mRNA-1273.

You May Also Be Interested In

• Boeing withdraws from Navy jet training system competition
• KBAT Group files for 6.25M share IPO at $4-$5/sh
• Lyell Immunopharma reports safety data for lymphoma CAR T-cell therapy